Key points are not available for this paper at this time.
Supplementary Figure S4. KIN-3248 efficacy is potentiated by MEK inhibitor treatment. Mice bearing the ICC-21 CDX model were treated daily with vehicle, trametinib 0.1 mg/kg, KIN-3248 5 mg/kg, KIN-3248 15 mg/kg or the combination. A. Serial measurements of tumor volume. n = 8 mice per group. Two-way ANOVA multiple comparisons with Tukey correction were used to analyze the data. ****, P
Balasooriya et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: